These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 29218397)
21. [Diagnosis of pancreatic intraductal papillary mucinous neoplasm]. Hong HS; Kim MJ Korean J Gastroenterol; 2008 Oct; 52(4):207-13. PubMed ID: 19077521 [TBL] [Abstract][Full Text] [Related]
22. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct. Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085 [TBL] [Abstract][Full Text] [Related]
23. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Schoedel KE; Finkelstein SD; Ohori NP Diagn Cytopathol; 2006 Sep; 34(9):605-8. PubMed ID: 16900481 [TBL] [Abstract][Full Text] [Related]
24. Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential. Maker AV; Hu V; Kadkol SS; Hong L; Brugge W; Winter J; Yeo CJ; Hackert T; Büchler M; Lawlor RT; Salvia R; Scarpa A; Bassi C; Green S J Am Coll Surg; 2019 May; 228(5):721-729. PubMed ID: 30794864 [TBL] [Abstract][Full Text] [Related]
25. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Yu J; Sadakari Y; Shindo K; Suenaga M; Brant A; Almario JAN; Borges M; Barkley T; Fesharakizadeh S; Ford M; Hruban RH; Shin EJ; Lennon AM; Canto MI; Goggins M Gut; 2017 Sep; 66(9):1677-1687. PubMed ID: 27432539 [TBL] [Abstract][Full Text] [Related]
27. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781 [TBL] [Abstract][Full Text] [Related]
28. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Maker AV; Katabi N; Gonen M; DeMatteo RP; D'Angelica MI; Fong Y; Jarnagin WR; Brennan MF; Allen PJ Ann Surg Oncol; 2011 Jan; 18(1):199-206. PubMed ID: 20717734 [TBL] [Abstract][Full Text] [Related]
29. [Intraductal papillary mucinous neoplasm of the pancreas (IPMN)--standards and new aspects]. Distler M; Welsch T; Aust D; Weitz J; Grützmann R Zentralbl Chir; 2014 Jun; 139(3):308-17. PubMed ID: 24241954 [TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic characteristics of patients with resected multifocal intraductal papillary mucinous neoplasm of the pancreas. Fritz S; Schirren M; Klauss M; Bergmann F; Hackert T; Hartwig W; Strobel O; Grenacher L; Büchler MW; Werner J Surgery; 2012 Sep; 152(3 Suppl 1):S74-80. PubMed ID: 22770954 [TBL] [Abstract][Full Text] [Related]
32. Pancreatic juice cytology as sensitive test for detecting pancreatic malignancy in intraductal papillary mucinous neoplasm of the pancreas without mural nodule. Kawada N; Uehara H; Nagata S; Tomita Y; Nakamura H Pancreatology; 2016; 16(5):853-8. PubMed ID: 27459913 [TBL] [Abstract][Full Text] [Related]
33. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes. Lahat G; Lubezky N; Loewenstein S; Nizri E; Gan S; Pasmanik-Chor M; Hayman L; Barazowsky E; Ben-Haim M; Klausner JM Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S750-7. PubMed ID: 25069861 [TBL] [Abstract][Full Text] [Related]
34. [Surgical management of intraductal papillary mucinous neoplasms]. Jang JY Korean J Gastroenterol; 2008 Oct; 52(4):220-5. PubMed ID: 19077523 [TBL] [Abstract][Full Text] [Related]
35. [Pancreatic tumor: progress in diagnosis and treatment. Topics: II. Intraductal papillary mucinous neoplasm of the pancreas (IPMN)/mucinous cystic neoplasm (MCN); 2. Pathology and pathobiology]. Furukawa T; Kuboki Y; Hatori T; Yamamoto M; Shibata N; Shiratori K Nihon Naika Gakkai Zasshi; 2012 Jan; 101(1):57-63. PubMed ID: 22413462 [No Abstract] [Full Text] [Related]
36. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes. Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840 [TBL] [Abstract][Full Text] [Related]
37. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas. Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573 [TBL] [Abstract][Full Text] [Related]